Oppenheimer Comments on Conformis, Inc.’s FY2023 Earnings (NASDAQ:CFMS)

Conformis, Inc. (NASDAQ:CFMS – Get Rating) – Equities research analysts at Oppenheimer upped their FY2023 EPS estimates for Conformis in a research note issued on Thursday, March 2nd. Oppenheimer analyst S. Lichtman now anticipates that the medical instruments supplier will earn ($5.57) per share for the year, up from their prior forecast of ($5.85). Oppenheimer has a “Outperform” rating and a $8.00 price objective on the stock. The consensus estimate for Conformis’ current full-year earnings is ($5.29) per share.

Separately, StockNews.com assumed coverage on shares of Conformis in a research note on Tuesday, November 29th. They issued a “hold” rating on the stock.

Conformis Price Performance

Shares of NASDAQ CFMS opened at $1.77 on Monday. Conformis has a 1-year low of $1.20 and a 1-year high of $18.78. The company has a market cap of $13.28 million, a price-to-earnings ratio of -0.25 and a beta of 1.09. The company has a debt-to-equity ratio of 0.38, a current ratio of 5.63 and a quick ratio of 4.04. The stock’s 50-day moving average is $2.59 and its two-hundred day moving average is $1.60.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Wasatch Advisors Inc. boosted its stake in Conformis by 9.7% during the 1st quarter. Wasatch Advisors Inc. now owns 20,030,298 shares of the medical instruments supplier’s stock valued at $12,495,000 after purchasing an additional 1,778,054 shares in the last quarter. State Street Corp boosted its position in Conformis by 4.2% during the first quarter. State Street Corp now owns 3,368,168 shares of the medical instruments supplier’s stock worth $2,101,000 after purchasing an additional 136,641 shares during the period. Renaissance Technologies LLC boosted its position in Conformis by 4.1% during the third quarter. Renaissance Technologies LLC now owns 4,763,691 shares of the medical instruments supplier’s stock worth $911,000 after purchasing an additional 188,200 shares during the period. Millennium Management LLC acquired a new position in shares of Conformis during the second quarter worth approximately $160,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Conformis during the fourth quarter worth approximately $91,000.

About Conformis

(Get Rating)

ConforMIS, Inc is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm’s products include iUni, iDuo, iTotal CR, and iTotal.